EDAP-TMS to Announce Second Quarter 2017 Financial Results on Wednesday, August 23, 2017
August 10 2017 - 04:31PM
PRESS RELEASE
Contact: Blandine
ConfortInvestor Relations / Legal AffairsEDAP TMS SA+33 4 72 15 31
72bconfort@edap-tms.com |
Investors:Rich CockrellCG
CAPITAL877.889.1972rich@cg.capital |
EDAP-TMS to Announce Second Quarter 2017
Financial Results on Wednesday, August 23, 2017
Conference Call to Review Results to be Held
Thursday, August 24, 2017
LYON, France, August 10, 2017 - EDAP TMS SA (Nasdaq:
EDAP), the global leader in therapeutic ultrasound, today
announced that it will release its financial results for the
second quarter ended June 30, 2017, after the close of the
financial markets on Wednesday, August 23, 2017.
An accompanying conference call will be conducted by Marc
Oczachowski, Chief Executive Officer, and François Dietsch, Chief
Financial Officer, to review the results. The call will be held at
9:00 AM ET, on Thursday, August 24, 2017. Please refer to the
information below for conference call dial-in information and
webcast registration.
Conference Details Conference Date: Thursday,
August 24, 2017 9:00 AM ET Conference dial-in: 877-269-7756
International dial-in: 201-689-7817 Conference Call Name: EDAP-TMS
Second Quarter 2017 Results Call Webcast Registration: Click
Here Following the live call, a replay will be available on the
Company's website, www.edap-tms.com, under "Investor
Info".
About EDAP TMS SAEDAP TMS SA markets today Ablatherm® for
high-intensity focused ultrasound (HIFU) for prostate tissue
ablation in the U.S. and for treatment of localized prostate cancer
in the rest of the world. HIFU treatment is shown to be a minimally
invasive and effective option for prostatic tissue ablation with a
low occurrence of side effects. Ablatherm-HIFU is generally
recommended for patients with localized prostate cancer (stages
T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy
treatment. Ablatherm-HIFU is approved for commercial distribution
in Europe and some other countries including Mexico and Canada, and
has received 510(k) clearance by the U.S. FDA. Ablatherm Fusion is
not FDA cleared yet. The Company also markets an innovative
robot-assisted HIFU device, the Focal One®, dedicated to focal
therapy of prostate cancer. Focal One® is CE marked but is not FDA
cleared. The Company also develops its HIFU technology for the
potential treatment of certain other types of tumors. EDAP TMS SA
also produces and distributes medical equipment (the Sonolith®
lithotripters' range) for the treatment of urinary tract stones
using extra-corporeal shockwave lithotripsy (ESWL) in most
countries including Canada and the U.S. For more information on the
Company, please visit http://www.edap-tms.com ,
and http://www.hifu-prostate.com.
Forward-Looking Statements
In addition to historical information, this press release may
contain forward-looking statements. Such statements are based on
management's current expectations and are subject to a number of
risks and uncertainties, including matters not yet known to us or
not currently considered material by us, and there can be no
assurance that anticipated events will occur or that the objectives
set out will actually be achieved. Important factors that could
cause actual results to differ materially from the results
anticipated in the forward-looking statements include, among
others, the clinical status and market acceptance of our HIFU
devices and the continued market potential for our lithotripsy
device. Factors that may cause such a difference also may include,
but are not limited to, those described in the Company's filings
with the Securities and Exchange Commission and in particular, in
the sections "Cautionary Statement on Forward-Looking Information"
and "Risk Factors" in the Company's Annual Report on Form 20-F.
# # #
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Feb 2024 to Mar 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Mar 2023 to Mar 2024